

113/LG/SE/MAY/2023/GBSL

May 30, 2023

To,  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001  
**Scrip Code: 509079**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
**Scrip Symbol: GUFICBIO**

Dear Sir/Madam,

**Sub.: Press Release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Company has cleared the physical audit of The Brazilian Health Regulatory Agency (ANVISA) successfully without any observation. The Company has received Good Manufacturing Practices Certificate from ANVISA for its manufacturing unit situated at Unit - 2, Survey No. 171, N. H. No. - 8, Near Grid, Kabilpore, Navsari - 396 424, Gujarat for its manufacturing line "Steriles: Lyophilized Powders". This will enable the Company to expand its business in the territory of Brazil.

Kindly take the same on record.

Thanking You,

Yours truly,

**For Gufic Biosciences Limited**

**Ami Shah**  
**Company Secretary & Compliance Officer**  
**Membership No. A39579**